financingCatalYm GmbH raises €50m to push visugromab developmentLatest NewsMunich-based immunooncology specialist CatalYm GmbH wants to use €50m from a Series C financing round to advance its anti-GDF15 antibody to Phase II development. Read more 22 November 2022 https://european-biotechnology.com/wp-content/uploads/2024/04/_c__PDPics_pixabay.com.jpg 540 960 Margarita Milidakis /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Margarita Milidakis2022-11-22 16:41:282024-07-16 12:18:54CatalYm GmbH raises €50m to push visugromab development